Cure51 clinches €15M to study cancer’s ‘exceptional survivors’

2024-03-21

Aiming to learn more about those who overcome particularly aggressive forms of cancer, Cure51 raised €15 million ($16.4 million) in a seed round led by Sofinnova Partners.

Other investors in the fundraising include Hitachi Ventures GmbH, Life Extension Ventures, Xavier Niel, and Datadog co-founder and CEO Olivier Pomel.

Founded in 2022, Cure51 is building a clinical and molecular database of “exceptional” cancer survivors, against which it is deploying new analytical techniques to investigate the molecular means by which the patients are able to live for long periods of time.

“Modern AI models require world class datasets to uncover novel biology and discover transformative medicines, and this is what Cure51 is uniquely creating for cancer patients,” said Hitachi’s Joanna Soroka.

Cure51 is working with five oncology centres in Europe: the Gustave Roussy Institute in Paris, the Leon Bérard Center in Lyon, the Charité Universitätsmedizin in Berlin, the Instituto Europeo di Oncologia in Milan, and the Vall d'Hebron in Barcelona.

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构

Sofinnova SARL